Abstract: Disclosed herein are methods of treating addiction to a dopamine-producing agent (e.g., amphetamine, cocaine, nicotine, opioids) in patient populations that do not exclude alcohol consumption during treatment.

Abstract: Disclosed is a novel combination therapy to reduce or prevent the acquisition of a conditioned response in a mammal comprising administering to the mammal a therapeutically effective amount of an aldehyde dehydrogenase (ALDH-2) inhibitor compound, such as a compound of Formula (I), in combination with a substance that produces the conditioned response, such as a medication containing a dopamine-producing agent such as an opioid, whereby the combination acts to reduce or prevent the acquisition of a conditioned response, and the deleterious side-effect of misuse, dependence, abuse, and/or addiction.

Abstract: Disclosed are novel isoflavone derivatives having the structure of Formula I which are useful as ALDH-2 inhibitors for treating mammals for dependence upon drugs of addiction, for example addiction to dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine, and alcohol.

Abstract: Disclosed are novel isoflavone derivatives having the structure of Formula I which are useful as ALDH-2 inhibitors for treating mammals for dependence upon drugs of addiction, for example addiction to dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine, and alcohol.

Abstract: This invention relates to methods for treating a patient suffering from neuropathic or nociceptive pain which may be mechanical, visceral, and/or inflammatory in nature, comprising administering a therapeutically effective amount of Ranolazine to a patient in need thereof.

Abstract: Disclosed are isoflavone derivatives having the structure of Formula I which are useful as ALDH-2 inhibitors for use treating in mammals suffering from psychiatric disorders such as, for example, depression, generalized anxiety, social phobia, panic disorder, and sleep disorders.

Abstract: Disclosed are novel isoflavone derivatives having the structure of Formula I which are useful as ALDH-2 inhibitors for treating mammals for dependence upon drugs of addiction, for example addiction to dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine, and alcohol.

Abstract: Disclosed are novel isoflavone derivatives having the structure of Formula I which are useful as ALDH-2 inhibitors for treating mammals for dependence upon drugs of addiction, for example addiction to dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine, and alcohol.

Abstract: This invention provides a method of mitigating/ameliorating one or more components of addictive behavior associated with chronic consumption of a substance of abuse, or withdrawal therefrom. The method typically involves administering to a subject in need thereof an adenosine A2A receptor antagonist in an amount sufficient to ameliorate said one or more components of addictive behavior.

Abstract: This invention provides to the discovery of the mechanism of a synergistic activity between dopamine D1 and D2 receptors and the exploitation of this mechanism to mitigate one or more symptoms associated with consumption of a substance of abuse. In certain embodiments, this invention provides a method of inhibiting nucleus accumbens spike firing in response to administration of a substance of abuse, where the method involves increasing activity of a slow A-type potassium current (IAS) in cells of the nucleus accumbens.

Abstract: The present invention relates to determinable effects of ethanol exposure on the cellular localization and abundance of specific proteins, referred to herein as ethanol indicative proteins. More specifically, the present invention is based, in part, on the discovery that the catalytic C&agr; subunit of cAMP dependent protein kinase (PKA), which is normally localized in the Golgi apparatus area, appears to translocate to the nucleus upon exposure of a cell to ethanol. The present invention is further based on the observation that the &dgr;-subunit of PKC translocates from the Golgi area to the perinucleus and the nucleus in response to ethanol exposure, while the &egr;-subunit of PKC migrates from the perinucleus into the cytoplasm. The present invention further relates to the discovery that the detectable amount of the regulatory subunit RI of PKA decreases, while the detectable amount of &agr;PKC, &dgr;PKC and &egr;PKC increases upon exposure of a cell to ethanol.

Abstract: A tile product having a substantially non-porous vinyl composition base and a multilevel embossing and gloss which has a mechanically embossed mortar-line surround and which is free of gloss defects formed by pockets of air trapped between the wear layer and embossing mold during embossing is produced by applying a vacuum to the press during embossing. Preferably, the tile is laminated in a hot press heated by RF energy and cooled in a cold press to reduce the temperature of the wear layer to below its glass transition temperature.